Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
NT$ 22.7
Key Takeaways
Risk factor
Very poor trading liquidity
Data is available to registered users only
Data is available to registered users only
Profitability factor
Strong growth
Data is available to registered users only
Data is available to registered users only
About
LAUNXP Biomedical Co. Ltd. is engaged in the development of medicines for tumor therapies. It also offers anti-cancer and antiproliferative drugs including virus-like nanoparticles and nanoparticles. The company was founded on September 24, 2015 and is headquartered in Taichung, Taiwan.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Data is available to registered users only
Buy
Sell